Xvivo Perfusion AB (OTCPK:XVIPF)
$ 42.9 1.67 (4.05%) Market Cap: 1.38 Bil Enterprise Value: 1.34 Bil PE Ratio: 67.14 PB Ratio: 7.03 GF Score: 86/100

Q2 2021 Xvivo Perfusion AB Earnings Call Transcript

Jul 13, 2021 / 12:00PM GMT
Release Date Price: $39.9
Operator

Ladies and gentlemen, welcome to the XVIVO Group Interim Report Q2 2021. I will now hand over to Dag Andersson, CEO. Sir, please begin.

Dag Andersson;publ;President;CEO
Xvivo Perfusion AB

()-&

Yes. good morning, good afternoon and good evening anywhere in the world you are right now and welcome to the second quarterly telephone conference 2021. I am happy to present with my CEO -- CFO, Kristoffer Nordstrom.

And as mentioned in the quarterly report, which was released this morning, we had a strong second quarter from many aspects. Sales, margins and EBITDA showed very positive performance. Sales in local currencies increased by 116% in the quarter. Gross margin of nondurable goods, 76% and EBITDA margin adjusted of 14%. These are very strong numbers. And on top of that, an organic growth of 82% for the thoracic business area also worth mentioning since this is actually an exceptionally strong number.

The level of recovery within organ transplantation varies from country to country. In the U.S

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot